However, we wish to emphasise the importance of considering such small but possibly significant risks in the management of individual patients: if the adverse effect does set in, it must be recognised and managed, and alternative treatments must be considered.
← all excerpts
Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses.
1
—
—